CLIC2. CTLA4. FCN1. KLRF1. MS4A1. TCL1A. TNFRSF10C c b. CD14+ monocyte. CD16+ monocyte macrophage m0 macrophage m1 macrophage m2.
Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases
Supplementary Information
Supplementary Figure 1 MAD=0.07 p=0.16
Supplem Figure 1
6
density
MAD=0.09 p=4.4e-02
4
MAD=0.21 p=3.16e-08 2.71
2
0 0.4
0.6
0.8
Median goodness of fit per platform immunoStates
LM22
IRIS
mentary Figure 1: Platform bias in cell mixture deconvolution. Density plots represen Platform in cell mixture deconvolution. Density plots representing the tion of median bias goodness of fit for each platform across all methods grouped by different distribution of median goodness of fit for each platform across all methods grouped ented by by fill color). Significance of platform is computed by ofestimating A different matrices (represented by fill bias color). Significance platform the biasMedian is e (MAD) of each distribution comparing to a null distribution that assumes computed by estimating the and Median Absolute itDistance (MAD) of each distribution and no t comparing it to a null distribution that assumes no technical variation between n between samples. samples.
Supplementary Fig Supplementary Figure 2 Correlations of estimated cell proportions between scaled and non−scaled methods
1.00 ● ●
0.75
0.50 ●
0.25 ●
0.00 Linear Model
Robust Regression
method
plementary Figure 2: Effect of rescaling expression data to deconvolution. Boxplot displayin l correlation between cell proportions estimated deconvolution with and without rescaling Effect of rescaling expression data to deconvolution. Boxplot displaying samplear Model = 0.989 +/0.002)cell or Robust Regression (r =deconvolution 0.843 +/- 0.034) multiple sa level(rcorrelation between proportions estimated with across and without s matrices. Center lines correspond median boxRegression and the lower and upper rescaling by either Linear Modelto(rthe = 0.989 +/- value 0.002)of oreach Robust (r = 0.843 +/- 0.034) across samples and basis matrices. Center lines correspond to the box correspond to theirmultiple first and the third quartiles, respectively. median value of each box and the lower and upper bounds of each box correspond to their first and the third quartiles, respectively.
a
c Supplementary Figure 3
a
c
CD14+ monocyte
2
0
CD4+ alpha beta T cell CD8+ alpha beta T cell
−2
CD56dim natural killer cell MAST cell eosinophil
−4
0
CD8+ alpha beta T cell
−2
gamma delta T cell
CD56dim natural killer cell MAST cell
myeloid dendritic cell
eosinophil
plasma cell
basophil
plasmacytoid dendritic cell
immuno
CD4+ alpha beta T cell
CD56bright natural killer cell
memory B cell
24
macrophage m1
neutrophil
naive B cell
19
2
macrophage m0
basophil
hematopoietic progenitor
12
4
CD14+ monocyte
macrophage m2
gamma delta T cell CD56bright natural killer cell
60
CD16+ monocyte
macrophage m1 macrophage m2
LM22 204
4
CD16+ monocyte macrophage m0
CD1E CD209 CD3G 60 CD40LG 204 431 CD8A CLIC2 12 19 44 CTLA4 FCN1 KLRF1242 MS4A1 TCL1A immunoStates TNFRSF10C
IRIS
CD1E CD209 CD3G CD40LG CD8A CLIC2 CTLA4 FCN1 KLRF1 MS4A1 TCL1A TNFRSF10C
b b
IRIS
neutrophil
−4
Supplementary Figure 3
hematopoietic progenitor naive B cell myeloid dendritic cell plasma cell memory B cell
plasmacytoid dendritic cell
Supp Figu
Creation of the immunoStates matrix. (a) Flow-chart describing the steps for the creation of the immunoStates expression matrix. (b) Heatmap showing expression of the immunoStates signature genes in target cell types. Genes expression values are displayed as z-scores per gene across all cell types. (c) Venn-diagram depicting the overlap between gene-sets between each basis matrix. Genes overlapping across all three matrices are listed on the left side of the diagram.
Supplementary Figure 4 Supplementary Figure 4 Linear Model
PERT
Quadratic Programming
Robust Regression
Support Vector Regression
LM22 genes using immunoStates expression values
75%
50%
25%
Goodness of fit (r) 0.9 0.8 0.7 0.6 0.5
GPL6480 GPL6102 GPL6947 GPL6104 GPL6244 GPL5175 GPL570 GPL571 GPL96
GPL6480 GPL6102 GPL6947 GPL6104 GPL6244 GPL5175 GPL570 GPL571 GPL96
GPL6480 GPL6102 GPL6947 GPL6104 GPL6244 GPL5175 GPL570 GPL571 GPL96
GPL6480 GPL6102 GPL6947 GPL6104 GPL6244 GPL5175 GPL570 GPL571 GPL96
0% GPL6480 GPL6102 GPL6947 GPL6104 GPL6244 GPL5175 GPL570 GPL571 GPL96
% samples
100%
Supplementary Figure 4: Increasing the amount of data to estimate expression values for genes in a basis matrix does not improve deconvolution accuracy. We used the datasets used to create immunoStates to calculate expression values for each gene in and deconvolved the technical evaluation We Increasing the amount of data toLM22, estimate expression values bias for genes incohort. a basis found increasing the amount of data to estimate expression value of a gene in a basis matrix did not increase matrix does not improve deconvolution accuracy. We used the datasets used to accuracy.
create immunoStates to calculate expression values for each gene in LM22, and deconvolved the technical bias evaluation cohort. We found increasing the amount of data to estimate expression value of a gene in a basis matrix did not increase accuracy.
Supplementary Figure 5
a
Healthy
a
1.00
● ●
IRIS 1.00 ● ● ●
● ● ●
● ●
● ● ●
● ● ●
● ● ●
● ●
0.75
● ●
●
● ● ● ●
● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ●
●
●
● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ●
Linear Model
0.50
b
1.00
0.25
● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ●
● ● ●
● ● ● ●
● ● ●
●●●●●●
●
● ● ● ● ●
●
● ● ●
0.50
●
● ●
● ● ●
0.25
IRIS
IRIS
●● ● ● ● ● ● ● ● ●
● ● ●
● ● ●
● ● ● ● ● ● ●
LM22
LM22
0.00
Linear Model PERT
● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ●
● ●
● ●
● ● ● ●
● ● ● ●
● ● ● ●
● ● ●
● ● ●
●
●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
0.00
●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ●
●
● ● ● ● ●
● ●
● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ●
● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ●
● ● ● ● ● ●
● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ●
● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ●
● ● ● ● ● ● ● ● ● ●
●
● Support Vector Quadratic● Robust Linear PERT Quadratic Robust Support Vector ● ● Vector ProgrammingRobust Regression Regression ● Regression QuadraticProgramming Robust Support Quadratic Support Vector ● RegressionLinear Model PERT
● ● ● Regression ● Programming Regression ● ● ● ●
Model
Programming Regression Regression
●
● ● Disease
DiseaseLM22
● ●
● ● ● ●
●
● ●
●
● ●
● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ●
● ● ● ● ● ●
immunoStates
IRIS
●
immunoStates
IRIS
●
● ● ● ● ● ● ●
●
● ●
● ● ●
● ● ● ● ●
LM22
● ● ● ● ● ● ● ● ● ● ● ● ●
Quadratic Robust Support Vector Programming Regression Regression
Linear Model
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
immunoStates ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
immunoStates ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ●
PERT
●
● ● ● ● ● ● ●
● ● ● ●
LM22
● ●
●
● ● ● ● ● ●
●
Solid Tissue
● ●
● ●
Linear Model
Solid Tissue
immunoStates
● ● ● ●
● ● ● ● ● ● ●
●
● ● ● ● ● ● ● ● ● ● ● ● ● ●
PERT
Blood Blood BloodSolid Tissue
BloodSolid Tissue
immunoStates
LM22
●
Quadratic Robust Support Vector Programming Regression Regression
● ● ● ● ● ● ● ●
PERT
●
PERT
● ●
Cancer Cancer
● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ●
●
● ● ● ● ● ● ● ● ● ●
●
Linear Model
● ● ●
● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ●
● ● ●
● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ● ●
●
● ●
●
● ● ● ●
● ●
● ● ● ● ● ● ●
●
●
● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
●● ●● ● ● ●● ● ● ● ●● ● ● ● ●● ●● ● ●
● ● ● ● ● ● ● ● ● ●● ●● ●● ● ● ●●
● ● ● ●
● ● ● ● ● ● ●
● ● ● ● ●
● ● ● ● ● ●
● ● ●● ● ● ●● ● ●
● ● ● ●● ● ● ● ●● ●
● ● ●
●
●
0.00
● ● ● ●
● ● ●● ● ●● ● ●
● ●
● ● ● ●
● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● Linear PERT Quadratic Robust Support Vector ● ● ● ● ● ● ● ● ● ● Programming Regression Regression PERT Model Quadratic Robust Vector Linear ● ● Support ● ● ● ● ●Regression ● ● ● ● ● ● Programming Regression Model ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● IRIS ● ● ● ● ● ● ● ● ● ● ● ● ● 1.00 ● ● ● IRIS● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 0.75 ● ● ● ● ● ● ● ● ● ● ● ● ●
●●●●●● ● 0.00 ● ● ●●● ● ●
● ●
0.25
● ● ● ●
● ●
● ●
0.75
0.50
● ● ● ● ● ●
●
0.75
● ● ● ● ● ● ● ● ● ● ● ●
● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ●
● ● ● ●
● 0.25 ●
25
00
● ●
● ●
●
Healthy Healthy
0.50
0.00
Goodness of Fit
50
● ● ●
● ● ● ● ●
●
b
●
1.00 0.25
75
● ●
● ● ● ●
●● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Supplemen Figure 5 Figure 5
immunoStates ● ● ● ●
●
● ●
●
● ●
0.50
● ● ● ●
● ●
● ●
●
● ●
● ●
00
● ●
● ●
● ● ● ●
● ● ● ●●
● ●
● ●
● ●
● ● ●
● ●
Suppleme
immunoStates
LM22
● ●
● ●
● ●
● ●
0.75
LM22 Healthy
IRIS
● ● ● ● ●
● ● ● ● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ● ●
● ● ● ● ● ● ●
Quadratic Robust Support Vector Programming Regression Regression
●
Programming Regression Regression Model Programming Regression Model diseased Programming Regression Regression Supplementary Figure 5: Goodness of fit Regression in healthy and samples. (a) Boxplots indicatin goodness of fit scores (y-axis) for blood-derived and tissue-derived samples in healthy donors (1383 samples Goodness of fit in healthy and diseased samples. (a) Boxplots indicating goodness across multiple for IRIS, LM22, and immunoStates. Center lines correspon Supplementary Figure deconvolution 5: Goodnessmethods of fit (x-axis) in healthy and diseased samples. (a) Boxplots indicati of to fit the scores (y-axis) for blood-derived and tissue-derived samples in healthy donors of each box and the lower upper boundssamples of each box correspond to their firstsample and th goodness of fitmedian scores value (y-axis) for blood-derived andand tissue-derived in healthy donors (1383 (1383 samples) across multiple deconvolution methods (x-axis) for IRIS, LM22, and third quartiles, respectively. (b) Same as in (a) in disease (2684 samples).Center lines correspo across multiple deconvolution methods (x-axis) forbut IRIS, LM22,samples and immunoStates. Linear Model
PERT
Quadratic
Robust Support Vector
Linear
PERT
Quadratic
Robust Support Vector
Linear
PERT
Quadratic
Robust Support Vector
immunoStates. Center lines correspond to the median value of each box and the to the lower medianand value of each box and lower upper bounds of each correspond their first and t upper bounds of the each boxand correspond to their firstbox and the third toquartiles, third quartiles, respectively. (b)as Same in (a) in disease samples (2684 samples). respectively. (b) Same in (a)asbut in but disease samples (2684 samples).
Supplementary Figure 6 Supplementary Figure 6 Blood
1.00
Solid Tissue
p < 2.2e-16
p < 2.2e-16
Pairwise Correlation of estimated proportions
p = 0.56 0.75
p = 0.001 ●
0.50
●
0.25
0.00
p < 2.2 e-16 Same Matrix Different Method
Same Method Different Matrix
p < 2.2e-16 Different Matrix Different Method
Same Matrix Different Method
Same Method Different Matrix
Different Matrix Different Method
Supplementary Figure 6: Deconvolution concordance by matrix and method across blood and solid tissue. Boxplots representing the distribution of pairwise correlation coefficients between estimated proportions for all matrices and deconvolution methods. Comparisons were divided in (1) pairs with the samesolid Deconvolution concordance by matrix and method across blood and signature matrix but run with different methods, (2) pairs with different signature matrices but run using the tissue. Boxplots the distribution correlation coefficients same method, and (3)representing pairs where both matrix and method of werepairwise different. Significance analysis was between estimated proportions fortest.allResults matrices deconvolution methods. performed using the Wilcoxon’s paired rank sum are shown and for samples containing blood cells or Comparisons were divided in (1) pairs with the same signature matrix but run with solid tissue biopsy from Lukk et al 2010.
different methods, (2) pairs with different signature matrices but run using the same method, and (3) pairs where both matrix and method were different. Significance analysis was performed using the Wilcoxon’s paired rank sum test. Results are shown for samples containing blood cells or solid tissue biopsy from Lukk et al 2010.
Supplementary Figure 7
LM22 ● ●
● ● ● ●
● ● ● ● ●
●
40
●
● ●●
● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ●
●
0
20
40
● ●
●
20
0
● ●
●
●
0
●
●
●
● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ●● ● ●● ●●●● ●● ● ●● ● ● ●●● ● ● ● ● ● ●● ● ● ● ● ●● ●● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ●● ●● ●● ●
● ● ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ●● ● ●● ● ●● ●● ●● ● ●● ● ●● ● ● ● ● ● ●●●● ● ●● ● ● ● ● ●● ●●●●● ● ●● ●●● ● ● ● ● ● ●● ● ● ●●● ● ●
● ● ●
●
10
40
● ● ● ● ●
60
●●
● ● ●
●
● ●
40
●
●
●
10
20
● ● ●
●
●
●
●● ●●
●● ●
●
● ● ●
●
●
40
●
●
● ●
● ●
●
● ●●
Flow Cytometry Cell Frequency (%)
●
●
●
●
●
● ● ● ●● ● ● ● ● ● ●● ● ●● ●●● ●● ● ● ● ● ●● ● ● ●● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ●●● ● ●● ● ● ● ●● ●● ●●● ● ● ● ● ●● ● ● ●●● ● ● ● ● ●● ●
● ●
●
●
●
● ●
● ● ● ●● ●● ● ● ● ● ●● ●● ●● ● ● ●●● ● ●● ●● ● ●● ● ●● ● ●● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ●●● ● ●● ●● ● ●●● ●● ● ● ● ● ● ●● ● ● ●● ● ● ●● ● ●● ● ●● ● ● ● ● ●● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●
20
40
Estimated Cell Proportion (%)
●
●
● ●
● ●
●
● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●● ● ●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ●● ●
20
60
10
40
● ●
CD14+ Monocyte
●
CD4+ T-Cell
20
30
CD8+ T-Cell
40
Gamma/Delta T-Cell ●
r = 0.86
20
●
memory B-Cell
● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●
Robust Regression
●
● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ●●● ● ● ● ●● ● ●● ● ● ●●● ● ●● ●● ● ● ● ●● ●●● ● ●● ●●●● ●●●● ● ●● ● ●●● ● ●● ●● ● ●●● ● ● ● ● ●● ●●● ● ●● ●● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ●● ● ●● ● ● ●
40 40
00
●
20 20
4040
naïve B-Cell NK
60
Estimated Cell Proportion (%)
immunoStates ●
r = 0.69
● ●
●
● ● ●
● ●●
●
● ● ●
●●
● ● ● ●
●
● ● ●
● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ●● ●● ● ● ● ●●● ● ● ●●●● ● ● ●● ● ●● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ●
0
●
● ●● ●● ● ●●
0
20 20
40
0
●
●
●●
Estimated Cell Proportion (%)
●
20
●
● ●
●
LM22 60
Quadratic Programming
●
●
Estimated Cell Proportion (%)
●
●● ●
● ● ● ●
●
●
immunoStates immunoStates
●●
00
●
30
● ●●
●
0
●
0
●
● ● ●
40
●● ● ●●● ● ●
●●
40
20
●
20
●
●
●
●
40 60
●
10
40
0
30
●
Estimated Cell Proportion (%)
r = 0.20
● ● ● ● ●●●● ● ● ● ●●●● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●
r = 0.79
60
LM22
r = 0.79 ●
IRIS Flow Cytometry Cell Frequency (%)
●
LM22
●
20 20
● ● ●
● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●● ●●● ●●●●●●● ●●● ● ● ● ●● ●● ● ● ●
60
●
● ●
● ● ●
Estimated Cell Proportion (%)
● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ●● ● ● ●● ● ●● ● ● ● ● ●●●● ● ● ● ● ● ● ●● ●●●●● ● ● ● ● ● ● ●●● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ●●● ● ● ●● ● ● ● ● ●● ● ●●●●●● ● ●● ● ● ●●● ● ● ●● ●● ● ● ● ● ● ● ●
00
●
●
●
0
●
●●
●
●
●
20
Linear Model
● ●● ●
Estimated Cell Proportion (%)
●
●
80
●●
● ●
0
● ●●
20
● ● ●
●
●
0
r = 0.29
●
IRIS ●
r =-0.09 ● ●
0
40
0
●
● ●
40
● ● ●
● ●
●
30
●
●
● ● ●
immunoStates ●
Flow Cytometry Cytometry Cell Cell Frequency Frequency (%) (%) Flow
Flow Cytometry Cell Frequency (%)
IRIS
20
●
● ●
20
●
0
20
●
●
●
60
Estimated Cell Proportion (%)
60
●
Flow Cytometry Cell Frequency (%)
●
● ●●
●
● ●
0
●
GSE65133
●
r = 0.78
Estimated Cell Proportion (%)
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
● ● ●
20
● ●
0
● ● ● ●
40
●
● ●
60
LM22
40
60
●●
●●
60
r = 0.85
0
●
● ● ●
IRIS
20
●
40
Estimated Cell Proportion (%)
60
●
Flow Cytometry Cell Frequency (%)
0
● ● ● ●● ● ● ● ●● ● ● ●● ●● ●●● ●● ● ●●● ● ● ● ● ● ●● ● ● ● ●●●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ●
immunoStates ●
r = 0.61
20
● ●
Flow Cytometry Cell Frequency (%)
20
● ● ● ●
60
Flow Cytometry Cell Frequency (%)
●
r =-0.02
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
IRIS 60
60
Estimated Cell Proportion (%)
● ●
● ●● ●
●
40
●
● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ●●● ●● ● ●● ● ●● ● ● ●● ● ● ● ● ●● ●● ● ● ● ● ●● ● ●● ●● ● ● ● ●●● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●●● ● ● ● ● ●
Support Vector Regression
●
● ●
●
●
● ●
● ●
20
0 40
●
r = 0.91
0
20
40
Estimated Cell Proportion (%)
60
Supplementary Figure 7
Supplementary Figure 8 LM22
immunoStates ●
●
r =-0.10
● ●●
0
0
0
20
40
10
60
20
0
0 10
20
30
40
50 20
0
5040
50
●
r = 0.50
● ●
●
75
●
0
Quadratic Programming
●●
●
● ● ● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ●●● ●● ● ● ● ● ●● ● ●●● ● ●● ● ●● ● ● ●● ●● ● ●● ●● ● ● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●● ●● ● ● ● ●● 20 ●● ● ●●●●●● ● ●●● ● ●●●● ● ● ● ●●●● ● ●● ●● ● ●● ●● ●●●● ●● ● ●●● ● ●● ●● ● ● ●● ●● ●● ● ● ● ● ●● ●●● ●● ● ●● ● ●● ●● ● ●● ● ●●● ● ● ● ● ●● ● ● ●●●●●● ● ●● ● ●●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ●● ●●● ● ●●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ●●● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ●● ● ● ●● ●●● ● ● ● ●● ●●● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●●● ● 0 ●
40
●
60 20
40
●
60
CD8+ T-Cell
Estimated Cell Proportion (%)
●
memory B-Cell
● ●
r = 0.33
0
20
40
60
80
20 0
●
r = 0.65
20
40
8040
0
Flow Cytometry Cell Frequency (%)
●
40
0
20
40
Estimated Cell Proportion (%)
60
● ●
●●
0 20
NK
60 60
●
r = 0.32●●
●
●
●
●
r = 0.65
● ●●
● ● ● ●●● ● ● ● ● ● ● ● ● ●● ● 40 ● ●● ● ● 40 ● ● ● ● ● ●● ● ●● ●● ● ● ●● ● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ●● ●● ● ● ● ●● ●● ● ● ●● ●● ● ● ● ● ●● ●●● ●● ● ● ●● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ●●● ●● ●● ● ● ● ●● ●● ● ● ● ● ● ● ●●● ● ● ● ● ●● ● ● ●● ● ● ●● ● ● ● ●● ●● ● ●● ● ● ●●●● ● ● ●● ● ●● ●●● ●● ● ● ●●● ● ● ● ●● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●● ●●● ● ●● ●● ●● ● ● ● ● ●●● ● ●● ● ● ● ● ● ● ● ●●● ● ● ●● ● ●● ●●● ●● ● ● ●● ● ● ●●● ●● ●● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ●● ●●● ●●● ●● ● ● ● ● ● ● ●●● ●● ● ● ●● ● ●●● ● ●●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● 20 20 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●● ● ●● ● ● ●●● ● ● ●● ● ●● ● ●●● ● ●● ● ●● ● ● ●●●● ● ● ●● ● ●●● ● ●● ●● ●●● ● ● ● ● ● ● ●● ● ● ●●●● ●● ● ● ●● ● ● ●● ●●●● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ●●● ● ● ● ● ● ●●● ● ● ●● ●● ● ● ●● ●● ● ● ●●● ● ●● ●●● ● ●● ●● ● ● ● ●●● ●● ●●● ● ● ● ●● ●● ●●●● ● ● ●● ● ● ●● ● ● ●●●●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ●●● ● ● ● ● ● ● ● ●● ● ●●● ● ●●● ● ●●●●●● ● ● ● ●● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ● ●● ● ● ● ● ●●● ● ● ● ●● ● ● ●● ● ●● ● ●●● ●● ● ● ● ● ●●● ● ● ●● ● ● ● ● ●● ●● ●● ● ● ●● ●● ● ● ● ● ● ● ● ● ●●● ●● ●● ●●● ● ●● ● ●● ● ● ● ●● ● ● ●● ● ● ●●● ● ● ● ● ● ● ● ●● ● ● ●●● ● ● ●● ● ● ● ●● ●● ● ●● ● ● ●● ● ●●●● ● ● ●● ●● ● ● ● ● ● ● ●●●●● ●●●●● ● ● ● ●●●● ● ● ● ● ● ●● ● ● ● ●●● ● ● ●●●●● ●●● ● ●● ● ● ● ● ●● ●●●● ● ●● ●●● ● ● ● ● ●● ●● ●● ● ●● ● ●● ●● ● ● ● ● ●● ●● ● ● ●●● ●● ● ●● ● ●● ●●● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ●● ● ● ● ● ●● ●●● ●●● ●●● ●● ●● ● ● ● ● ●●●●● ● ● ● ●●●●●● ● ●●● ● ● ● ● ●● ● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ●●●●●● ●● ●● ●● ● ●● ● ● ●● ●● ●● ●●● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ●●●● ●● ●● ● ●●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●● ● ●● ● ●● ●● ●●● ● ● ●●●●● ●● ● ●● ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●●● ● ● ●● ● ●● ● ● ● ●● ●●● ●● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ● ●●●● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ●●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ●● ●● ● ●● ●● ● ● ● ● ● ●● ●● ● ● ● ●● ● ●●● ● ●●● ●●● ●● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●●● ● ● ● ● ● ● ●● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ● ●●●● ●●● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●●● ●●● ●● ● ● ● ● ● ●● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ●● ●●●● ●● ●● ●●● ● ● ● ● ● ● ● ● ● ● ●● ● ●●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●●●● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ●● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●●●● ● ●● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ●● ● ●● ● ● ● ● ● ● ●●● ● ● ●●●●●●●● ● ●● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●●● ●● ●● ● ●● ● ● ● ●● ●● ● ●●● ●● ●0●● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ●●● ● ●● ● ● ● ● ●● ●●● ● ● ● ● ●● ● ●● ● ●●●●●●● ● ● ● ● ●● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ●● 0 ●●●●●●●●
0
naïve B-Cell
immunoStates ●
r = -0.07
20
Robust Regression
Estimated Cell Proportion (%)
LM22
● ● ● ●
60
Estimated Cell Proportion (%)
CD14+ Monocyte CD4+ T-Cell
●
immunoStates ●
Estimated Cell Proportion (%)
Flow Cytometry Cell Frequency (%)
5040
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
0
0
30
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ●● ● ●● ● ● 40 ● ●● 40 ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ●● ● ●●● ● ● ●● ●● ●●● ● ●●●● ● ● ● ● ● ●● ●● ●● ● ●● ● ● ●● ●● ● ●● ● ●● ● ● ● ●● ●● ● ● ● ●● ● ● ●●●●● ●●● ● ● ●●● ●● ● ● ● ● ●● ●● ● ●●● ● ●● ● ●● ●● ●● ● ● ● ● ● ● ●● ●●●● ● ● ● ● ●●● ● ● ●●● ● ●● ● ● ● ● ●● ●● ● ● ● ● ●●●● ●● ● ● ●● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●●●●● ●● ● ●● ● ●● ● ● ● ● ●● ●●● ●● ● ● ●● ●● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ●●●●●● ● ●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● 20 20 ● ● ● ● ● ● ● ● ● ● ● ●●● ●● ● ● ●● ● ●● ● ●●● ●● ● ● ● ● ● ●● ● ● ●●● ●● ●● ●●● ● ●●● ●● ●● ●●● ● ● ●● ●●●● ● ●● ●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ●● ●●●● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●●●● ● ● ●● ●●● ● ● ● ●● ● ●● ● ● ● ●●● ●● ●● ●●● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ●● ● ●● ●● ● ●● ● ●● ●● ● ● ●●● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ●● ●● ●● ● ● ● ● ●●● ● ●●● ● ● ● ● ● ● ● ●●● ●● ●● ● ●● ● ● ●●●● ● ● ●●● ● ● ● ● ●● ● ●●●●● ● ●●● ● ● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ● ●●●● ● ●● ● ●●● ● ●●●● ● ● ● ● ● ●●● ● ● ●● ● ● ● ● ●● ●● ● ● ●●●●● ● ●● ●● ● ● ●● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ●● ●● ● ● ●●● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ● ● ●● ●● ● ● ● ●●●● ●● ● ●●● ● ●● ● ● ●● ●● ●● ● ● ●● ●● ● ● ● ● ●● ● ●● ● ● ●● ●● ● ● ● ● ● ● ●● ● ● ●● ● ● ●●●● ●● ● ●● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ●●●● ●● ● ●●● ●● ● ● ●● ● ● ● ● ● ● ●●●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ●●● ● ● ●● ● ● ●● ● ● ●● ● ●●● ● ● ● ● ●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ●● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ●●●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●●● ●● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ●●●●● ● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●●● ● ● ● ● ●●●● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●●●● ●●● ● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ● ●● ●●● ● ● ● ●● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ●●● ●●● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ●●●●● ●●● ●● ● ●● ● ● ●●● ●● ● ●●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ●● ●● ● ● ● ● ● ●● ●●●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ●●● ●● ●● ●●● ● ●●●● ●● ● ● ●● ●●●●● ● ●● ●●● ● ● ● ● ● ●●●●●● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ●● ●●● ●●● ● ●● ●● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ●●●● ● ● ●● ●● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●● ●● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●●● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●● ●● ● ● ● ●● ●● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● 0●● ● ● ● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ● ●● ● ●●●● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ●● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● 0 ●
immunoStates IRIS
20
25
● ● ●●
40
r = -0.05
Estimated Cell Proportion (%)
r =-0.25
20
Estimated Cell Proportion (%)
LM22
● ●
0
0 40 10
●
● ●
Estimated Cell Proportion (%)
20
80
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 40 ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ●●● ●● ● ● ●●● ● ●● ●● ● ● ● ● ● ● ● ● ● ●●●●● ● ● ● ●●● ● ● ● ●●● ● ● ● ● ● ●● ● ●● ● ●● ● ● ●●● ● ● ● ● ● ● ●●● ● ● ● ● ●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ●● ● ●●●●● ●● ● ●●●●● ● ● ● ● ●●● ● ● ● ●●● ● ● ●●● ●● ● ● ● ●● ●● ● ●● ● ●● ● ● ● ● ●●● ●●●● ● ● ● ● ● 20 ●● ● ●●●● ●● ● ● ●● ●● ●●●●●● ● ● ●●● ● ● ●● ● ●● ●● ● ●●● ● ●● ●● ● ●●●● ● ●●●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ●● ● ●● ●● ● ●● ● ●● ● ●●● ● ●●● ● ● ● ● ● ● ● ●● ● ● ●● ●●●● ●●● ●● ● ●●●● ● ● ● ●●● ●●● ●● ● ● ● ● ●● ● ● ● ● ●●●●●●● ● ● ●● ●●● ● ●● ●●● ●● ● ● ●● ● ●● ● ● ●●●●● ● ●●●●● ● ●● ● ● ● ● ●● ● ● ●●●● ● ● ●●● ●● ● ●● ● ● ●●●●● ● ●● ●●●●●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ●● ● ●●● ● ● ● ●● ●●● ● ● ●●● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ●●●● ● ● ●● ●●● ● ●●●●● ● ●● ● ●● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ●● ●●● ●● ● ● ● ● ● ●● ●●●● ● ● ●●●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ●● ● ● ● ● ● ● ●●●● ● ●● ●● ● ●● ●● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ●● ● ● ●● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●● ●● ●● ● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ● ●● ●● ● ●● ● ●● ● ●● ● ● ● ● ●●● ● ● ●● ● ● ●●●●● ● ● ●● ●● ● ● ● ●● ● ●●●●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●●● ●● ● ● ● ● ● ● ● ● ● ●● ● ●● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ●●● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ●● ●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ●●● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●●● ● ●● ●● ●● ●● 0●●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●●●●● ●●● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●●●● ● ●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ●●●●●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ●● ● ● ●
immunoStates IRIS
40
60 30
●
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
r = 0.41
Linear Model
immunoStates
● ●
0
40
LM22 ●
20
20
Estimated Cell Proportion (%)
immunoStates IRIS
GSE59654
● ●
●
0
0
Estimated Cell Proportion (%)
40
●
●
r = 0.59
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● 40 ● 40 ● ● ●● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ●●● ● ●● ● ● ●● ● ● ● ● ●●● ● ●● ●● ●●● ● ● ●●●● ● ● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ● ●● ●●● ● ● ●● ● ● ●● ● ● ●● ● ● ●● ●●●● ● ● ● ● ●● ● ● ● ●●●● ● ●● ● ●● ●● ●● ● ● ●● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●●● ●● ● ●● ● ● ● ●● ● ●● ●● ● ● ● ●● ● ● ●● ● ● ●● ● ●●● ● ●● ●●●● ● ●●● ● ●● ●●●●●●● ●●● ● ● ● ● ●● ● ●●● ●● ● ● ● ●● ● ●●● ●●●●●● ● ●●● ●●●● ● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ●● ●●● ● ● ●●●● ●●● ●●● ● ●● ● ●●● ● ● ●● ●● ● ●● ● ● ●●● ● ● ● ●●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ●● ●●●●● ●●●● ● ● 20 ●● ●● 20 ●● ●●●● ● ● ●● ●●●● ● ● ●● ●● ● ●●●● ● ●●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●● ●●●● ●● ●●● ●● ● ●●● ● ● ● ●●● ● ● ● ●● ●● ●● ●●● ● ●● ● ●● ● ● ● ● ● ●● ● ●● ● ● ●●● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●●● ● ● ●●●●● ● ●● ●●● ●● ●● ● ● ●● ●●●● ●● ● ● ● ● ●●● ● ●●●● ● ● ●● ● ● ●● ●●●● ● ● ● ●● ● ●● ● ● ● ● ●● ●● ●● ● ● ●● ●● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ●● ●●●● ●● ● ● ●● ● ●●● ●● ● ●● ●● ● ●● ● ● ●● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ●● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ●● ● ●● ● ● ● ●● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ●●● ●● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●● ●● ●● ● ● ● ● ● ● ● ●●● ● ●● ●● ● ● ● ● ● ● ●● ● ●● ● ●●●● ● ●●●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ●●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ●●● ● ●●● ● ● ● ●● ●● ●● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ●●● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●● ●● ● ● ● ●●● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ●● ● ●● ●● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ●●● ● ● ● ●● ● ●●● ● ●● ● ●● ●● ● ● ●●● ●● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ●● ● ●●●●●● ● ● ● ●● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ●●● ●●●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●●● ● ●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●● ● ● ● ● ●●●●● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●●● ● ●● ● ● ● ● ● ● ●●● ● ● ● ●● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●●● ● ● ● ● ● ● ●● ●●● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●● ●● ● ● ● ● ● ● ●● ● ● ● ● ●●● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ●● ●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ●●● ● ● ●● ● ● ● ● ●●● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ●●● ●● ● ●● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●●●● ● ● ● ●● ●● ● ● ● ● ●● ●● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ●
● ●
Flow Cytometry Cell Frequency (%)
0
●
●
r = 0.22
Flow Cytometry Cell Frequency (%)
20
● ●
Flow Cytometry Cell Frequency (%)
40
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
●
Flow Cytometry Cell Frequency (%)
immunoStates IRIS
20
40
60
Estimated Cell Proportion (%)
040
20
40
Estimated Cell Proportion (%)
Support Vector Regression Supplementary Figure 8
Supplementary Figure 9
● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ●● ●● ● ● ● ● ● ● ● ●●●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●●● ●●● ● ● ●● ● ●●●● ● ●●● ●
●
40
20 ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●
0
25
50
60
20 ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ●●
75
20
●
40
20
0
20
20
40
20 ●● ● ● ●● ●● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ●● ● ● ●● ● ● ● ● ● ●● ● ● ●●
20
80
30
40
40
20
20 ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●
0
20
40
60
● ●
20 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
20
Estimated Cell Proportion (%)
20
20 ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●
20
40
60
Estimated Cell Proportion (%)
80
Complete Blood Count (%)
●● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ●●● ●● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ●●●● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●
PMNs 40
60
80
Lymphocytes
●
● ● ● ●
r = 0.81
●●●● ●●● ●● ●●● ● ●●●● ●●●● ●●● ●● ● ● ● ●● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ●● ● ● ●● ● ●● ● ● ● ●
60
● ●
40 ●
20 ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
●
60
20
●
● ●● ● ● ● ● ●● ● ●●● ●● ●●● ● ● ●● ● ●● ● ● ●●● ● ●● ● ● ● ● ● ●● ●● ● ● ●● ● ● ● ●● ●● ●● ● ● ● ●●● ● ●●● ●●● ● ●●● ● ●
40
Monocytes
Robust Regression
60
Estimated Cell Proportion (%)
immunoStates
80
● ●
●
40
r = 0.55
● ● ●● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●●● ● ● ● ● ●● ● ● ● ●● ● ●● ● ● ● ●● ●● ● ● ●●●●●●● ● ●●● ● ●● ● ●
40
80
Estimated Cell Proportion (%)
r = 0.01
Quadratic Programming
Estimated Cell Proportion (%)
LM22 ● ● ● ● ● ● ●● ●●● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ●● ●● ● ● ● ● ● ● ● ●●● ● ● ● ● ●● ●● ●● ● ●● ●● ●● ● ● ● ●● ●● ● ●●● ● ●● ●
60
● ● ● ● ● ●● ● ●●● ● ● ●●● ● ●●● ● ● ● ● ●● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ●●● ● ● ●● ● ●● ●● ● ● ● ● ● ● ● ●● ●● ●● ● ●● ●
40
IRIS 80
●
60
80
●
●● ● ● ● ●● ●● ● ● ● ● ●● ● ●● ●● ● ● ●● ●● ●● ●●●●●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●●● ● ● ●●● ●● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ●●● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ●
50
Complete Blood Count (%)
40
● ●
immunoStates
80 Complete Blood Count (%)
● ● ● ● ●●●● ● ● ●●● ●●● ● ● ● ●● ● ● ●● ●●● ●●● ● ●● ● ● ● ● ● ● ● ● ●●● ●●● ●● ●● ● ● ● ● ●● ●● ●● ● ● ● ● ●● ●●● ●● ●●● ● ●● ● ●
●
60
● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ●●● ● ●● ● ● ●● ● ● ● ●● ● ●● ● ● ● ●●● ●●● ● ●● ● ● ● ●● ●● ● ● ● ● ● ● ●●● ● ● ● ●● ● ●● ● ● ●●
r = 0.98
Estimated Cell Proportion (%)
r =-0.03
● ● ● ● ●● ● ● ●●● ● ●● ● ●● ●● ●● ● ●●●● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ●●● ●● ● ●● ● ● ●●● ● ● ● ●● ● ● ● ● ●● ● ● ● ●●●
40
60
LM22 ● ● ● ● ●
Model
Estimated Cell Proportion (%)
● ● ●● ●● ●● ●●●● ●● ●● ● ●● ● ● ●● ●● ● ● ●● ●● ● ●● ● ● ●● ● ●● ●● ● ● ●● ●●● ● ● ● ● ●● ● ●● ● ● ●● ●● ● ● ● ● ●● ● ●● ● ● ● ●● ● ●
●
40
60
Stanford-Ellison 2011 Linear
immunoStates
60
IRIS
Complete Blood Count (%)
20
60
● ● ● ● ● ●●● ● ● ●● ● ●● ● ● ● ● ● ●● ●● ●● ● ● ● ● ● ●● ● ● ● ●●● ● ● ● ● ● ● ●● ● ● ● ●● ● ●● ● ● ● ●●● ● ●● ● ●●● ●● ● ●●● ●●
r = 0.60
Estimated Cell Proportion (%)
● ● ● ●● ● ●● ● ●●● ● ● ● ●● ● ●● ●● ● ●●●● ● ● ● ●●●● ● ● ●● ● ●● ●● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ●●● ● ● ● ● ● ●● ●● ●● ● ●● ● ● ●
40
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ●● ● ● ●● ●
Complete Blood Count (%)
● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●
Complete Blood Count (%)
Complete Blood Count (%)
60
80
r = 0.26
● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Complete Blood Count (%)
60
LM22 ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ●
0
40
● ●●● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ●● ●●● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ●●● ● ●● ● ● ●● ● ●●●● ● ●● ● ● ●
r = 0.86
Estimated Cell Proportion (%)
IRIS 80
60
80
● ● ●● ●● ● ● ● ●● ● ●● ● ●● ●● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ●●●● ● ● ●● ● ● ● ● ●●●● ● ● ●● ● ● ●
●
40
Estimated Cell Proportion (%)
80
immunoStates ● ●● ● ● ●●● ●●●●● ● ●● ● ● ●●● ●●● ● ●● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ●● ●●● ●● ● ● ●● ●● ● ●● ● ●● ● ●
r = 0.43
●
60
● ● ● ● ● ●●● ● ●●● ● ● ● ● ●●● ●● ●● ● ●●●● ● ● ● ● ● ● ●● ● ●●● ● ● ● ● ● ●●● ●● ●● ● ●●● ● ● ● ● ●●● ●●●● ● ● ●● ●●● ●● ● ● ● ● ● ●
40
20 ● ●● ●● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●●
20
● ● ●● ●● ●● ● ●● ● ● ● ●●● ● ● ● ● ●● ● ● ●● ● ●●●● ● ● ●● ●● ●● ●●● ● ● ● ●●● ●● ● ● ●● ●● ● ●● ● ●● ●● ●● ●●●● ● ● ● ●● ●●● ●● ● ●
40
80
r = 0.40
60
Estimated Cell Proportion (%)
●
Complete Blood Count (%)
60
80
r =-0.07 Complete Blood Count (%)
Complete Blood Count (%)
LM22 ●● ●● ● ●● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ●
Complete Blood Count (%)
IRIS 80
r = 0.82
60
● ●● ● ● ● ● ●● ● ● ●●●● ●● ●●● ●● ● ● ● ●● ●● ● ●● ● ●●● ●● ● ● ●● ●●● ● ● ●● ● ● ●●● ● ● ● ● ●● ● ●● ● ● ● ●● ● ●● ● ●● ● ● ● ● ● ●● ●
●
40
●
●
● ●● ●● ● ●●● ● ●●● ●● ● ● ● ● ●● ●● ●● ● ● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●●
20 ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
20
40
Estimated Cell Proportion (%)
60
Support Vector Regression Supplementary Figure 9
Supplementary Figure 10 IRIS
LM22
immunoStates ●
●
● ● ● ● ● ● ● ● ● ● ● ●●●● ● ●● ● ●● ● ●● ● ●● ●● ● ● ● ● ●●● ● ● ● ● ● ●● ● ● ● ●●● ●● ● ●●●● ●●●● ● ●
40
20 ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●●
0
20
40
60
60
20 ● ● ● ●●●● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●
0
80
● ● ● ● ● ● ●● ● ● ●● ●●● ● ● ● ●● ● ● ● ● ●● ● ●● ●● ●● ● ●● ● ● ●● ●●●●● ●●● ●● ● ● ● ●● ● ● ●● ● ● ●● ● ● ●
40
10
20
Estimated Cell Proportion (%)
●
30
40
IRIS
20 ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●
0
20
40
80
60 ●
20 ● ● ● ●● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●
●
0
60
● ●● ● ● ● ● ●● ● ●●●●● ● ●●● ● ● ● ●●● ● ● ●● ●● ●●● ● ● ● ● ● ● ● ● ● ●●●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●
●
20
30
40
0
50
20 ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
20
40
60
r = 0.66
● ● ● ● ● ● ● ●● ●● ● ● ● ● ●● ●● ● ●●●● ●● ●● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ● ●●●● ●● ● ●● ● ● ● ●● ●● ● ● ● ● ● ●●●● ● ● ● ●● ●● ● ●●● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ●● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●
60
40
20 ● ● ● ●●● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●●●● ● ● ●● ● ● ● ●●
10
20
30
40
80
r = 0.85
60
80
40
20 ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●
0
50
Estimated Cell Proportion (%)
20
40
40
20 ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ●
40
60
Estimated Cell Proportion (%)
80
Complete Blood Count (%)
● ● ● ● ● ●● ● ● ● ●●●● ● ●● ● ● ●● ● ●● ●● ●● ●● ● ● ● ● ● ● ● ● ● ●●● ●● ● ● ●●● ● ● ● ●● ●● ● ● ●● ● ● ● ●● ● ●● ●
r = 0.60
60 ●
40
20 ● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●●● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ●●●
0
Robust Regression
60
Estimated Cell Proportion (%)
●
80
r = 0.06
Monocytes
immunoStates
● ● ●● ● ● ●●●● ● ● ● ● ●●● ●● ● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●●● ● ●●● ● ●● ●●●● ● ● ● ●● ●● ● ● ● ●● ●
Lymphocytes
● ● ●● ● ● ● ● ●● ● ●●●●●● ● ●● ●● ● ● ● ● ● ● ● ● ● ●●● ● ●●● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ●● ● ●● ● ● ●● ●●● ● ● ● ●● ● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ●●●●● ●●● ● ●● ● ●● ● ●
60
LM22
20
PMNs 40
●
●
0
80
Quadratic Programming
immunoStates
●
IRIS
60
20
●
● ●●● ● ●●● ●● ● ●●● ● ●●● ● ● ● ● ●●● ●● ● ● ● ● ● ●●● ●●● ●● ●●●● ● ● ● ●● ●● ● ● ● ●● ● ● ● ●● ● ● ●● ●
Estimated Cell Proportion (%)
Complete Blood Count (%)
● ●● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ●● ●● ● ●● ● ● ●●●●● ● ● ●●●●●●● ●●● ●● ● ●● ●
Complete Blood Count (%)
Complete Blood Count (%)
80
Estimated Cell Proportion (%)
Complete Blood Count (%)
20
● ●● ● ● ● ●● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ●● ● ●● ● ● ● ●● ●●●● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ●●● ● ●● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●●● ● ●●
Estimated Cell Proportion (%)
r = 0.01
40
80
60
●
● ●● ● ● ● ● ● ● ●●● ● ● ●● ●● ● ● ● ●● ●● ● ● ● ●●● ● ● ● ● ●● ● ● ● ●●● ● ●● ●●● ● ● ● ●● ● ● ● ●● ● ●
0
40
LM22
0
r = 0.97
60
●
●
60
40
●
80
● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●●● ●●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ●●● ● ●● ● ● ●●● ● ●● ● ● ●●
40
IRIS 80
20
Model
immunoStates
r = 0.59
Estimated Cell Proportion (%)
0
● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Stanford-Ellison 2012 Linear
Estimated Cell Proportion (%)
Complete Blood Count (%)
● ●● ●● ● ●● ●● ●● ●● ● ●● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ● ●● ●● ●●● ● ● ●● ●● ●
40
0
20
●
r = 0.29 Complete Blood Count (%)
Complete Blood Count (%)
● ●● ● ● ●● ●● ●● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●● ●● ● ● ● ● ● ● ●● ●● ●● ● ●● ●
60
0
40
0
50
● ● ●● ● ● ● ● ● ● ● ● ●● ● ●●● ● ●● ● ● ● ● ● ● ● ● ●● ●●● ● ●●● ● ● ● ● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●● ●● ●●● ● ● ●● ● ●●● ● ●●● ● ●●● ●● ● ● ● ●● ● ● ●● ●
60
LM22 ●
80
r = 0.90
Estimated Cell Proportion (%)
20
● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ●● ● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ●● ●● ● ● ● ● ●● ●●● ● ●●● ● ● ●● ●● ●● ●● ●● ●●● ● ● ●●● ● ● ●● ●● ●● ● ● ● ●● ● ● ● ●●●● ● ●
40
Estimated Cell Proportion (%)
●
80
●
60
Complete Blood Count (%)
0
r = 0.48
80
●●● ● ● ●●● ● ● ●●●●●●● ● ● ●●● ● ● ● ●●● ● ●● ● ●● ● ●● ● ● ● ● ● ●● ●● ●● ● ● ●●●● ●● ● ● ● ●● ●● ● ● ●
Complete Blood Count (%)
60
80
r =-0.02
●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ●●● ● ●● ● ● ● ● ●●● ● ●●● ●
Complete Blood Count (%)
Complete Blood Count (%)
80
r = 0.89
60
40
20 ●● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ●
0
20
●● ● ● ● ●● ●●● ●● ●●● ● ●● ● ● ●●● ● ● ●● ● ● ● ● ● ● ●● ● ● ●●●● ● ●● ●●●●● ● ● ● ●●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●● ●●● ● ● ● ● ● ●● ●● ● ●● ● ●●●● ● ●●● ● ● ● ● ●● ● ●●● ●● ●● ● ● ●●●● ●● ● ● ● ● ● ● ● ● ● ●
40
60
Estimated Cell Proportion (%)
● ●
Support Vector Regression Supplementary Figure 10
Supplementary Figure 11 LM22
50
r = 0.02
● ● ●● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ● ●● ● ●● ● ●● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ● ●● ● ● ● ● ●●● ● ● ● ● ●
●
25 ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●
0
20
40
60
75
50
25
● ● ● ● ● ● ● ●● ● ● ●● ● ●●●● ● ● ●● ● ●● ● ●● ●●● ● ●● ● ● ● ● ● ● ● ●●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ●●● ●● ●●● ●● ●●● ● ● ● ● ●●● ● ● ●●● ● ● ● ●●●● ● ● ● ●● ●●● ● ● ●●● ● ●●●● ● ●● ● ●● ●● ● ●● ●● ●● ● ●● ●● ● ●● ●● ● ● ●● ● ● ●● ●● ● ● ●● ● ●
r = 0.91
80
20
Estimated Cell Proportion (%)
●● ●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ●●
10
20
30
40
75
50
25
● ● ●● ● ● ● ● ● ● ● ●●● ● ● ●●●● ● ● ● ● ● ●● ● ● ● ●●●●●●● ● ●● ● ●●● ●● ● ●● ● ● ●●● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ●● ●● ● ● ● ●●●● ●● ●● ● ●●●● ● ●● ● ● ●● ● ● ●● ●● ●●●● ● ●●●●●
50
20
●● ● ●● ● ● ●
● ● ● ● ●●●● ●●● ● ● ● ●● ●●● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ●● ●●●● ● ● ● ● ● ● ● ●● ●●●●● ● ● ● ● ●
●
25 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
25
50
75
50
25
75
●
40
50
25
0
r = 0.84
30
40
20
40
60
Estimated Cell Proportion (%)
75
PMNs
80
75
50
25
● ● ●● ●● ● ●● ● ●● ●● ● ● ●● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ●●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ● ● ● ● ● ●●● ●● ●●●●● ● ● ● ●●● ●● ●● ● ● ●● ● ● ●●● ●● ● ●● ●● ● ● ● ● ● ●● ● ● ●● ● ● ●●● ● ● ●● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ●●●● ●●● ●● ● ● ● ●●
10
Lymphocytes
20
30
40
Monocytes
Robust Regression
50
Estimated Cell Proportion (%)
immunoStates ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ●●● ● ●●●● ●● ●● ● ● ●● ● ●● ●●
r = 0.94
● ● ● ●● ● ● ●
50 ●
25
60
r = 0.76
50
●
● ●● ● ● ● ●●● ●● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ● ● ●●● ●● ● ●● ●● ●● ● ● ●● ●●● ●●●● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ●●●●● ● ● ● ● ● ● ●
20
40
● ● ●●
60
Estimated Cell Proportion (%)
●
Complete Blood Count (%)
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Complete Blood Count (%)
25
●● ● ● ● ●●● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ●● ● ● ● ●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ●
40
●
● ●
20
Quadratic Programming
Estimated Cell Proportion (%)
LM22
50
● ● ●●● ● ●● ● ● ● ●● ● ●● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ●● ● ● ● ●●●● ● ●● ● ● ●● ● ●● ● ● ● ●●● ●●● ●● ● ●● ● ● ● ●● ● ● ● ●● ● ● ● ●●●● ●● ● ● ●● ● ● ●●● ●● ●●● ● ●●●● ● ● ● ● ● ●● ●● ● ●●● ● ● ●● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
immunoStates
●
r = 0.82
60
r = 0.59
Estimated Cell Proportion (%)
IRIS
Complete Blood Count (%)
75
60
● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ●● ● ● ●●●● ●● ● ● ●● ● ● ● ●●●● ● ●● ●●● ●● ● ● ● ● ●● ● ●● ● ● ● ● ●● ● ● ● ● ● ●● ● ●●● ●● ● ●●● ●● ●● ● ● ●●● ●● ● ●● ● ● ● ● ● ● ● ●● ●● ●●●● ●● ● ●● ● ● ● ● ● ●
20
Estimated Cell Proportion (%)
0
●
Complete Blood Count (%)
r = 0.12
●● ● ● ● ●● ●●● ● ● ●● ●● ●● ● ●● ● ● ● ●●● ● ● ●● ● ● ●● ●● ● ● ● ● ●● ● ● ●● ● ● ●●
Complete Blood Count (%)
Complete Blood Count (%)
● ●● ● ● ● ●●●● ● ●● ●●● ●●● ●● ● ●● ●● ● ● ● ●● ● ● ●● ● ● ● ● ●● ●● ● ●● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ●
LM22 ●
40
Model
Estimated Cell Proportion (%)
Estimated Cell Proportion (%)
IRIS
75
20
Stanford-Ellison 2013 Linear
immunoStates
r = 0.92
Estimated Cell Proportion (%)
●
● ● ● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ●●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ●● ● ● ● ● ●● ●● ● ●● ● ● ● ●● ●● ● ● ● ●● ● ●●● ● ● ●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●● ●● ● ● ● ● ●● ● ● ● ● ●● ● ● ●●● ● ● ●● ● ●● ●● ● ●
r = 0.87
60
Complete Blood Count (%)
25
0
25
●
Complete Blood Count (%)
Complete Blood Count (%)
● ● ● ● ● ●● ● ●●●●● ●● ● ● ●●● ● ●● ●● ●●● ● ● ●●●●●●● ●●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ● ● ● ●●● ● ●●● ●● ●● ● ● ●●● ●● ● ● ● ●●● ●● ●● ●● ● ● ● ●● ● ● ● ● ● ● ●●● ● ● ● ●
50
50
50
LM22
r = 0.65
75
75
Estimated Cell Proportion (%)
IRIS 75
40
Complete Blood Count (%)
75
immunoStates ●
● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ● ●● ●● ● ● ● ●● ● ●● ●● ● ● ● ● ●● ● ●● ● ● ● ● ●●
Complete Blood Count (%)
Complete Blood Count (%)
IRIS
75
50
25
● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●●●●● ● ● ●● ● ● ● ●● ●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●●●● ● ● ● ●●● ● ●● ●● ● ● ● ● ● ●● ●● ● ●● ● ●● ●● ● ●● ●●●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ●● ● ● ●●● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●● ●● ● ● ● ●● ●●● ● ● ● ●● ● ●●● ● ● ●
r = 0.87
10
20
30
40
50
60
Estimated Cell Proportion (%)
Support Vector Regression Supplementary Figure 11
Supplementary Figure 12 GSE65133 PERT
r = 0.20
60 ●
● ● ●
●
● ● ●
●
40
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
60
LM22 ●
● ● ● ●
●● ● ● ●●
20
0
● ●● ● ●●● ● ● ● ● ●● ●● ● ● ●● ● ● ●● ●● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ●● ●●● ● ● ●● ● ● ● ● ●●●● ● ●● ●● ●● ● ●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ●● ●
0
10
20
30
Estimated Cell Proportion (%)
●
●
40
immunoStates ●
r = 0.78
60
● ●
● ● ● ●
●
●
●
●
●
●
●
40 ● ●
●
● ●●
●
●
●● ● ●●●
20
0
● ● ●● ● ● ● ● ● ●●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ●●● ●● ●●● ● ●●● ●●● ●● ●● ● ●●●●● ●● ●● ● ● ● ● ●● ●● ● ● ●● ●● ● ●● ●●● ●● ● ● ●● ● ● ●●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●
0
10
●
Flow Cytometry Cell Frequency (%)
IRIS
20
30
●
CD14+ Monocyte
●● ●
● ● ● ● ● ● ●
40
●
CD4+ T-Cell
●
●
●
CD8+ T-Cell
● ●
●●
● ●
●
● ●● ● ● ● ●● ●● ● ● ● ● ● ●● ● ● ●● ●● ●● ● ● ● ● ●● ● ● ●● ● ● ●●● ● ● ● ● ●● ● ●● ● ● ● ● ● ●● ● ●● ●●●● ● ●● ● ● ● ● ●●● ● ●●● ●● ●● ● ● ●●● ●● ●●● ● ● ● ●● ●● ●● ●
20
0
Estimated Cell Proportion (%)
●
r = 0.48
0
10
20
Gamma/Delta T-Cell memory B-Cell
●
naïve B-Cell NK 30
Estimated Cell Proportion (%)
Supplementary Figure 12
Supplementary Figure 13
GSE59654 PERT
LM22
r = -0.33 ● ● ●
40
20
0
● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●●● ● ●● ● ● ●● ● ● ● ● ●●● ●● ● ●●● ● ● ● ●●●●●● ●● ● ● ● ●●● ● ●● ● ●●● ● ●● ●●●● ● ●● ● ● ● ● ●● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ●●● ● ● ● ● ●● ● ● ●● ● ●● ●● ●● ● ●● ● ● ● ● ● ●●● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ●● ● ● ●●●● ● ●● ● ●● ●●● ● ●●● ● ● ● ●● ● ● ●● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ●●● ●● ● ● ● ● ● ●●● ●●● ●● ● ●● ● ● ● ●● ●● ● ●●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ●●● ● ●●● ●● ● ●●● ●●● ●● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ● ● ●●●● ● ● ● ●● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●●● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ●
0
10
20
30
Estimated Cell Proportion (%)
40
immunoStates ●
r = 0.64
● ●
● ●
40
20
0
●
●●
● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ●● ●● ● ● ● ● ● ● ●●● ● ●●● ● ● ●●● ● ●● ● ● ● ●● ●●●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●●● ● ● ●●●● ●●● ●● ● ●● ● ●●● ●● ●● ●● ●● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ●● ●●●● ● ● ● ● ● ●● ● ● ● ● ●● ● ●●● ● ●●● ● ●●●● ● ● ●●● ● ● ● ● ●● ● ●●● ● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●
0
20
r = -0.03
●
40
Estimated Cell Proportion (%)
●
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
● ●
Flow Cytometry Cell Frequency (%)
IRIS
● ●
40
20
0 60
CD14+ Monocyte
●
● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ●● ● ● ● ● ●● ● ●●● ● ●●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ●●● ● ● ● ● ●● ● ● ● ● ● ●●● ●● ● ● ●● ● ● ● ● ●●● ● ●● ●● ● ● ●●● ● ●● ● ● ● ● ● ● ● ●● ● ●● ● ● ●●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ● ● ●●● ●● ● ● ●●●● ● ●●●● ● ● ● ● ● ● ● ●● ●● ● ● ●● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ●● ●●● ●●● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ●● ●● ● ● ●● ●● ● ● ● ● ●● ● ●● ● ●● ●● ● ●●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●●● ●●●●●● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ●● ●● ● ● ● ●● ● ● ● ●● ●● ● ● ● ●● ● ● ● ● ● ● ● ●● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ●● ● ● ● ●● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ●● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●●● ● ●● ● ● ●● ●● ● ● ● ●● ● ●● ●● ● ● ● ● ● ●
0
10
20
30
CD4+ T-Cell CD8+ T-Cell memory B-Cell naïve B-Cell ● ●
NK
● ● ●
40
50
Estimated Cell Proportion (%)
Supplementary Figure 13
Supplementary Figure 14 IRIS
LM22
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
75
● ● ● ● ● ● ● ● ●
●
25 ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
0
50
25
0
0
r=0
75
r = 0.91
40
60
80
0
50
Lymphocytes Monocytes
25
r = 0.84
50
2013
50
2013
2013
20
Estimated Cell Proportion (%)
r = 0.75 PMNs
75
25
25
75
0
75
50
Complete Blood Count (%)
r = 0.16
75
2012
25
PERT
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
25
2012
50
Complete Blood Count (%)
r = -0.17
75
2012
Complete Blood Count (%)
50
0
0
0
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
r = 0.78
2011
25
50
75
2011
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
●
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
r = 0.64
75
2011
50
r = -0.14
Stanford-Ellison 2011-2013
immunoStates
25
0
20
40
60
Estimated Cell Proportion (%)
0
20
40
60
Estimated Cell Proportion (%)
Supplementary Figure 14
Correlation plots between measured and estimated proportions. (7) Correlation plots of estimated (x-axis) and measured cell proportions (y-axis) for each method and matrix combination for samples in GSE65133. Correlation is measured by Pearson’s correlation coefficient. (8) Same as in (7) for GSE59654. (9,10,11) Same as in (7) for Stanford-Ellison 2011, 2012, and 2013 sample cohorts respectively. (12,13,14) Same as in previous figures but using the PERT method.
Supplementary Figure 15 ●
r = 0.20
●
● ●
●
● ● ● ● ●● ● ● ● ● ● ●● ● ●● ●●● ●● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ●●● ● ● ● ● ●● ● ●
20
●
●
●●
● ●
● ●
●
●
40
0
●
●
0
20
60
● ● ● ● ●
● ●●
● ● ●
● ● ● ●
●
● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ●●●● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ●● ● ●● ● ●● ● ● ● ● ● ● ● ●● ●
●
40
●
● ●
40
20
●
● ● ●
●●
0
●
immunoStates
r = 0.69
0
● ●
60
●
r = 0.91
●
● ●
40
20
40
●
● ●
● ● ●
●
● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●●●● ●● ● ● ● ●●● ● ●● ● ● ●● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ●● ●●● ● ● ● ●
0
Estimated Cell Proportion (%)
Supplementary Figure 15
● ●●
0
20
Estimated Cell Proportion (%)
b
CD14+ Monocyte CD4+ T-Cell
20
40
60
CD8+ T-Cell
Estimated Cell Proportion (%)
Gamma/Delta T-Cell IRIS
LM22 ●
60
● ●
● ● ● ●
● ●
●
40
●
●
● ●
● ●
20
● ●
●
● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●
0
10
immunoStates ●
60 ● ● ●
● ●
●
●
●
●●
●
● ●
40
● ●● ●
●
●
20
● ● ●
●
●
●
● ●
●
● ●
● ●● ●
● ● ● ●
0 20
30
40
Estimated Cell Proportion (%)
50
10
20
30
40
Estimated Cell Proportion (%)
50
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
●
● ● ● ●
Flow Cytometry Cell Frequency (%)
60
LM22 Flow Cytometry Cell Frequency (%)
IRIS
Flow Cytometry Cell Frequency (%)
Flow Cytometry Cell Frequency (%)
a
memory B-Cell ●
60
● ●● ●
●
40
●
●
NK
● ●
20 ● ● ●
0
●
●
●
0
●
● ●
naïve B-Cell
●
●
●
● ● ● ● ● ● ● ●● ● ● ●
● ● ●● ●
20
40
60
Estimated Cell Proportion (%)
Supplementary Figure 15: Example of systematic under- and over-estimation of cell proportions in cell mixture deconvolution. (a) Correlation plots of estimated (x-axis) and measured cell proportions (y-axis) in GSE65133 for all matrices using Support Vector Regression. (b) Highlighted CD4+ T-cell (yellow) and Monocyte (red) cell proportion estimates against measured values. Solid lines represent the best fit with a Example of systematic over-estimation of cell proportions in cell linear model, whereas the dashed lineunderrepresentand the 45-degree diagonal.
mixture deconvolution. (a) Correlation plots of estimated (x-axis) and measured cell proportions (y-axis) in GSE65133 for all matrices using Support Vector Regression. (b) Highlighted CD4+ T-cell (yellow) and Monocyte (red) cell proportion estimates against measured values. Solid lines represent the best fit with a linear model, whereas the dashed line represent the 45-degree diagonal.
n data from Affymetrix, immunoStates outperformed both Affymetrix-specific basis f the deconvolution method used. Similar comparison is also present in Figure 4, where orts were profiled using Affymetrix. As shown in Figure 4, immunoStates consistently ymetrix-specific basis matrices irrespective of the deconvolution method used.
Supplementary Figure 16
100 60
60
40
75
30
40
40
50
20
20 25
20
10
00
0
0
20
40
0
6010
20
40 20
60
0
30 10
20
30
naïve B-Cell NK
Quadratic Programming
Flow Cytometry Cell Frequency (%)
Estimated Cell Proportion (%)
100 60
60
40
75 40
40
50 20
20 25
00
20
0 0
20
40
0
10 60
20
20
40
60
0 30
10
20
30
40 40
Estimated Cell Proportion (%)
Support Vector Regression
Flow Cytometry Cell Frequency (%)
Robust Regression
Flow Cytometry Cell Frequency (%)
immunoStates r= r = 0.86
Flow Cytometry Cell Frequency (%)
matrices and deconvoluted rofiled using platform As expected, GPL10558 is d number of a GPL10558s missing a cell types. deconvoluted 0558-specific was inverse timated and proportions, od used (first
Flow Cytometry Cell Frequency (%)
’s suggestion, we created two Illumina-specific basis matrices. One of these two basis PL10558 as it GPL10558-specific Illumina-specific immunoStates basis matrix basis matrix only sorted immunoStates r = -0.71 r = 0.58 r = 0.79 r = 0.79 ion profiles platform (8 ; the second Linear matrix was Model immune cell CD14+ Monocyte CD4+ T-Cell that were CD8+ T-Cell immunoStates the Illumina Gamma/Delta T-Cell r = -0.74 r = 0.24 r = 0.79 r = 0.79 memory B-Cell asets, 1,670
-0.72
r = 0.43
r = 0.86
100 60
60
75
40
40
40
50 20
20 25
00
20
0 0
20
40
60
0
20
20
40
40 60
0
20
40 60
60
Estimated Cell Proportion (%)
immunoStates r= r = 0.91
-0.65
r = 0.32
60
r = 0.91 60
50
75
40
40 50
40 30 20
20 25
20
10 0
0 0
20
40
60
0 20
20
40
60
40
0
20
40
Estimated Cell Proportion (%)
Estimated Cell Proportions (%)
Figure R2: Comparison of Illumina-specific basis matrices with immunoStates.
ne cell types GPL10558-specific basis matrix, used in the first column, was created using only n usingComparison all sorted immune cell gene expression profiles GPL10558;with Illumina-specific of Illumina-specific basisusing matrices immunoStates. GPL10558mina, which basis matrix, used in the second column, was created using sorted immune cellonly sorted immune specific basis matrix, used in the first column, was created using an Illuminagene expression profiles using any Illumina microarrays; the third column used cell gene expression profiles using GPL10558; Illumina-specific basis matrix, used in immunoStates for deconvolution. Irrespective of the method used, estimated cell with the moresecond column, was created using sorted immune cell gene expression profiles proportions using immunoStates has higher correlation than both Illuminawever, it still using any Illumina microarrays; the third column used immunoStates for when deconvoluting GSE65133 that was generated using e cell deconvolution. types specific basis matrices Irrespective of the method used, estimated cell proportions using microarrays, GPL10558. naïve B immunoStates cells, Illumina-based has higher correlation than both Illumina- specific basis matrices when was low to moderate correlation betweenthat estimated proportions measured deconvoluting GSE65133 was cellular generated usingandIllumina-based microarrays, cond column in Figure R2). In contrast, immunoStates has consistently high correlation GPL10558.
portions (third column in Figure R2).
lts demonstrate that our proposed one-size-fits-most single matrix has higher accuracy basis matrix for each microarray platform.
Supplementary Table 1 Datasets used to measure platform bias
GSE
GPL
Brand
Samples
GSE38958
GPL5175
Affymetrix
115
GSE37912
GPL5175
Affymetrix
74
GSE21942
GPL570
Affymetrix
29
GSE19314
GPL570
Affymetrix
58
GSE22356
GPL570
Affymetrix
30
GSE55098
GPL570
Affymetrix
22
GSE17114
GPL570
Affymetrix
29
GSE17393
GPL571
Affymetrix
15
GSE23832
GPL6244
Affymetrix
12
GSE14577
GPL96
Affymetrix
15
GSE11907
GPL96
Affymetrix
122
GSE11909
GPL96
Affymetrix
115
GSE9006
GPL96
Affymetrix
105
GSE3365
GPL96
Affymetrix
68
GSE15573
GPL6102
Illumina
33
GSE18885
GPL6104
Illumina
127
GSE33463
GPL6947
Illumina
102